- Home
- INMB vs ENTA Comparison
INMB vs ENTA Comparison
Compare INMB & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ENTA
- Stock Information
- Founded
- INMB 2015
- ENTA 1995
- Country
- INMB United States
- ENTA United States
- Employees
- INMB N/A
- ENTA N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- ENTA Health Care
- Exchange
- INMB Nasdaq
- ENTA Nasdaq
- Market Cap
- INMB 112.0M
- ENTA 127.8M
- IPO Year
- INMB 2019
- ENTA 2013
- Fundamental
- Price
- INMB $4.40
- ENTA $6.28
- Analyst Decision
- INMB Strong Buy
- ENTA Buy
- Analyst Count
- INMB 2
- ENTA 4
- Target Price
- INMB $21.00
- ENTA $19.50
- AVG Volume (30 Days)
- INMB 215.6K
- ENTA 537.1K
- Earning Date
- INMB 10-31-2024
- ENTA 02-05-2025
- Dividend Yield
- INMB N/A
- ENTA N/A
- EPS Growth
- INMB N/A
- ENTA N/A
- EPS
- INMB N/A
- ENTA N/A
- Revenue
- INMB $42,000.00
- ENTA $67,635,000.00
- Revenue This Year
- INMB N/A
- ENTA $11.80
- Revenue Next Year
- INMB N/A
- ENTA $3.99
- P/E Ratio
- INMB N/A
- ENTA N/A
- Revenue Growth
- INMB N/A
- ENTA N/A
- 52 Week Low
- INMB $4.32
- ENTA $5.70
- 52 Week High
- INMB $14.74
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- INMB 37.57
- ENTA 31.04
- Support Level
- INMB $4.74
- ENTA $5.70
- Resistance Level
- INMB $5.16
- ENTA $6.56
- Average True Range (ATR)
- INMB 0.38
- ENTA 0.74
- MACD
- INMB -0.05
- ENTA -0.11
- Stochastic Oscillator
- INMB 5.56
- ENTA 14.91
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.